Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, ...

An OB/GYN was terse in her feedback, saying she needed an answer to inquiries from patients on whether their ovarian cancer ...

The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

KARACHI: The Karachi Port Trust handled 231,829 tonnes of cargo comprising 170,448 tonnes of import cargo and 61,381 tonnes ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

In a report released today, Anil Shenoy from Barclays maintained a Buy rating on Elementis (ELM – Research Report), with a price target of ...

In a report released yesterday, Sebastian Bray from Berenberg Bank maintained a Buy rating on Elementis (ELM – Research Report), with a price ...